8 results on '"Rodríguez-Montolio, Joana"'
Search Results
2. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
- Author
-
Caronna, Edoardo, José Gallardo, Victor, Egeo, Gabriella, Millán Vázquez, Manuel, Nieves Castellanos, Candela, Membrilla, Javier A., Vaghi, Gloria, Rodríguez-Montolio, Joana, Fabregat Fabra, Neus, Sánchez-Caballero, Francisco, Jaimes Sánchez, Alex, Muñoz-Vendrell, Albert, Oliveira, Renato, Gárate, Gabriel, González-Osorio, Yésica, Guisado-Alonso, Daniel, Ornello, Raffaele, Thunstedt, Cem, Fernández-Lázaro, Iris, and Torres-Ferrús, Marta
- Subjects
SEX factors in disease ,BOTULINUM A toxins ,CORPORATE directors ,HEALTH services administration ,CLUSTER headache ,MEDICAL specialties & specialists ,MIGRAINE aura - Published
- 2024
- Full Text
- View/download PDF
3. Incidence and outcoMes of MInor stroke and high-risk traNsient ischEmic attack in NordicTus: IMMINENT study
- Author
-
Ramos-Araque, María E., Castellanos, María del Mar, Naya Rios, Lucía, López-Cancio Martínez, Elena, Molina-Gil, Javier, Marta Moreno, Javier, Tejada Meza, Herbert, Temprano-Fernández, María Teresa, Antón-González, Celia, Vidal-de Francisco, Diana, Tejada García, Javier, Maciñeiras Montero, José Luis, Vicente Alba, Pablo, García-Sánchez, Juan Manuel, Aguilera-Irazabal, Borja, Martínez-Zabaleta, Maite, Díez, I.N., Pinedo Brochado, Ana, Azcune-Calle, Itxaso, Freijo Guerrero, María del Mar, Moreno-Estebanez, A., Palacio-Portilla, Enrique Jesús, Manrique Arregui, L., Rodríguez-Yáñez, Manuel, Santamaría Cadavid, María, Timiraos Fernández, Juan José, Herrero-Infante, Yolanda, Trejo-Gabriel-Galán, José María, Echavarría-Iñiguez, Ana, Tejero Juste, Carlos, Rodríguez-Montolio, Joana, Julián Villaverde, Francisco José, Moreno García, María Pilar, López-Mesonero, Luis, Redondo-Robles, Laura, Aymerich, Nuria, Korroza, J., Arenillas, Juan, Ramos-Araque, María E., Castellanos, María del Mar, Naya Rios, Lucía, López-Cancio Martínez, Elena, Molina-Gil, Javier, Marta Moreno, Javier, Tejada Meza, Herbert, Temprano-Fernández, María Teresa, Antón-González, Celia, Vidal-de Francisco, Diana, Tejada García, Javier, Maciñeiras Montero, José Luis, Vicente Alba, Pablo, García-Sánchez, Juan Manuel, Aguilera-Irazabal, Borja, Martínez-Zabaleta, Maite, Díez, I.N., Pinedo Brochado, Ana, Azcune-Calle, Itxaso, Freijo Guerrero, María del Mar, Moreno-Estebanez, A., Palacio-Portilla, Enrique Jesús, Manrique Arregui, L., Rodríguez-Yáñez, Manuel, Santamaría Cadavid, María, Timiraos Fernández, Juan José, Herrero-Infante, Yolanda, Trejo-Gabriel-Galán, José María, Echavarría-Iñiguez, Ana, Tejero Juste, Carlos, Rodríguez-Montolio, Joana, Julián Villaverde, Francisco José, Moreno García, María Pilar, López-Mesonero, Luis, Redondo-Robles, Laura, Aymerich, Nuria, Korroza, J., and Arenillas, Juan
- Abstract
[Abstract] Background. Our primary aim was to investigate the incidence of non-cardioembolic minor acute ischemic stroke (AIS) and high-risk transient ischemic attack (TIA) and to identify predictors of stroke recurrence/death and severe bleeding. We also evaluated the rates of TIA, major vascular events, therapeutic management and predictors of poor functional outcome at 3 months in these patients. Methods. We retrospectively reviewed data from all stroke patients evaluated at the emergency department of 19 hospitals belonging to the NORDICTUS stroke network between July and December 2019. Consecutive patients with non-cardioembolic minor AIS (NIHSS ≤5) and high-risk TIA (ABCD2 ≥6 or ipsilateral stenosis ≥50%) were included. We recorded clinical, neuroimaging and therapeutic variables. Follow-up was performed at 30 and 90 days. Functional prognosis was assessed with the modified Rankin scale score (mRS). Results. Of 8275 patients, 1679 (20%) fulfilled IMMINENT criteria (1524 AIS/155 TIA), resulting in a global incidence of 48/100,000 inhabitants per-year. Recurrent stroke/death occurred in 73 (4.3%) patients. Extracranial ipsilateral stenosis (>50%): HR 1.999 (95% CI: 1.115–3.585, p = 0.020) and lack of hyperacute cerebral arterial assessment: HR 1.631 (95% CI: 1.009–2.636, p = 0.046) were associated with recurrent stroke/death at 90 days. Intracranial stenosis was associated with poor prognosis (p = 0.044). Reperfusion therapy was given to 147 (9%) and urgent double antiplatelet therapy (DAPT) to 320 (21%) patients. Conclusion. Twenty percent of our stroke patients presented as non-cardioembolic high-risk TIA or minor AIS. Extracranial ipsilateral stenosis and lack of hyperacute cerebral arterial assessment were predictors of stroke recurrence/death; intracranial stenosis was associated with poor outcome. Despite current recommendations there was a low penetrance of DAPT., [Resumen] Introducción. Nuestro objetivo principal fue investigar la incidencia de ictus minor no cardioembólico y ataque isquémico transitorio (AIT) de alto riesgo, además de identificar predictores de recurrencia de ictus/muerte y sangrado grave. Evaluamos los porcentajes de AIT, eventos vasculares mayores, manejo terapéutico y predictores de mal pronóstico funcional. Métodos. Estudio retrospectivo de todos los pacientes con ictus evaluados en urgencias de 19 hospitales de la RED NORDICTUS entre julio-diciembre de 2019. Se incluyeron pacientes consecutivos con ictus minor no cardioembólico (National Institute of Health Stroke Scale [NIHSS] ≤ 5) y AIT de alto riesgo (ABCD2 ≥ 6 o estenosis ipsilateral ≥ 50%). Registramos variables clínicas, de neuroimagen y terapéuticas. Se realizó seguimiento a los 30 y 90 días. El pronóstico funcional se determinó mediante la escala de Rankin modificada (mRS). Resultados. De 8.275 pacientes, 1.679 (20%) cumplieron criterios del estudio IMMINENT (1.524 ictus/155 AIT), la incidencia global fue 48/100.000 h habitantes-año. Hubo recurrencias de ictus/muerte en 73 (4,3%) pacientes. La estenosis extracraneal ipsilateral (>50%): HR 1.999 (IC 95%: 1.115-3.585); p = 0,020 y la ausencia de estudio cerebrovascular hiperagudo: HR 1.631 (IC 95%: 1.009-2.636); p = 0.046, fueron predictores de ictus/muerte a 90 días. La estenosis intracraneal se asoció a mal pronóstico (p = 0,044). Se administró terapia de reperfusión a 147 (9%) y doble antiagregación a 320 (21%) pacientes. Conclusión. Un 20% de los pacientes se presentó como ictus minor o AIT de alto riesgo. La estenosis extracraneal ipsilateral y la ausencia de estudio neurovascular hiperagudo fueron predictores de ictus/muerte; la estenosis intracraneal se asoció con mal pronóstico. A pesar de las recomendaciones actuales hay baja penetrancia de doble antiagregación.
- Published
- 2024
4. COVID-19 Vaccination Coverage and Associated Factors in Patients with Multiple Sclerosis
- Author
-
Hernández-García, Ignacio, primary, Rodríguez-Montolio, Joana, additional, Almeida-Zurita, Monserrath, additional, Cheli-Gracia, Dionisio, additional, Sahuquillo, Belén del Moral, additional, Aibar-Remón, Carlos, additional, and Garcés-Redondo, Moisés, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Influenza Vaccination among Multiple Sclerosis Patients during the COVID-19 Pandemic
- Author
-
Hernández-García, Ignacio, primary, Garcés-Redondo, Moisés, additional, Espinosa-Rueda, Judit, additional, Rodríguez-Montolio, Joana, additional, Bengoa-Urrengoechea, Irantzu, additional, and Aibar-Remón, Carlos, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Early Wearing-Off Effect of OnabotulinumtoxinA in Chronic Migraine: A Prospective Real-Life Study.
- Author
-
Rodríguez-Montolio, Joana, Navarro-Pérez, María Pilar, Almeida-Zurita, Monserrath, and Santos-Lasaosa, Sonia
- Subjects
- *
BOTULINUM A toxins , *MEDICATION abuse , *MIGRAINE , *LONGITUDINAL method , *PATIENTS' attitudes - Abstract
Objective: Chronic migraine (CM) is a significant public health problem that affects 2.2% of the global population. Onabotulinumtoxin A (OnabotA) is a safe and effective prophylactic treatment for patients with CM. The standard injection interval for OnabotA is 12 weeks. Nevertheless, some patients experience a wearing-off effect (WOE) in the weeks preceding the next scheduled cycle. The objectives of this study are to determine the prevalence of early WOE, to analyze variables that could be clinical predictors and to specify which interval is the most appropriate to define the existence of this phenomenon. Methods: This is a prospective single-center study of consecutive adult patients with CM who, after failing previous prophylactic therapies, started OnabotA treatment following the PREEMPT protocol between June and December of 2021. Results: A total of 59 patients (93.2% female, age 44 ± 12 years) were included. A total of 37 patients (64.9%) fulfilled medication overuse criteria. Of the total patients, 40.6% reported WOE and this was more frequent after the first cycle (35.6%). Depression and anxiety disorder was a statistically significant clinical predictor of WOE (OR 3.4; CI 95% 1.22–10.84; p = 0.028). A better cut-off point to consider WOE seems to be at 10 weeks. Conclusions: Early WOE is common in patients on OnabotA treatment for CM. Individualizing the standard 12-week injection, using total doses of 195 U, and managing psychiatric comorbidities with pharmacological and non-pharmacological strategies may improve treatment outcomes and reduce OnabotA WOE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Utilidad del índice kappa en el diagnóstico de esclerosis múltiple y validación de valores de referencia en la Comunidad de Aragón
- Author
-
Saldaña Inda, Ignacio, primary, Aparicio Pelaz, Diego, additional, Rodríguez Montolio, Joana, additional, Sebastián Torres, Berta, additional, Iñíguez Martínez, Cristina, additional, and Inda Landaluce, Mercedes, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Influenza Vaccination Coverage among Multiple Sclerosis Patients: Evolution over Time and Associated Factors.
- Author
-
Hernández-García, Ignacio, Garcés-Redondo, Moisés, Rodríguez-Montolio, Joana, Bengoa-Urrengoechea, Irantzu, Espinosa-Rueda, Judit, and Aibar-Remón, Carlos
- Subjects
VACCINATION coverage ,INFLUENZA vaccines ,MULTIPLE sclerosis ,MULTIPLE regression analysis ,BIVARIATE analysis - Abstract
Our objective was to determine the influenza vaccination rate in a Spanish cohort of multiple sclerosis (MS) patients. A retrospective cohort study was carried out. Patients who attended the MS unit of the Lozano Blesa Hospital of Zaragoza between January 2015 and 2020 were included. The variables were obtained by reviewing the specialized and primary care records. Associations between receiving the vaccine in each flu season and the other variables were analyzed using bivariate analysis and multiple logistic regression models. A total of 260 patients were studied, with a median age of 31 years at the time of diagnosis. A total of 62.3% (162/260) were women. Vaccination coverage ranged from 20.4% in the 2015–2016 and 2016–2017 seasons to 41.5% in the 2019–2020 season (p = 0.000). Having been vaccinated in the previous season (ORa: 16.47–390.22; p = 0.000) and receiving a vaccination recommendation from the hospital vaccination unit (ORa: 2.44–3.96; p < 0.009) were associated with being vaccinated. The coverage is in an intermediate position compared to other countries. It is necessary to improve the referral system of these patients to the hospital vaccination unit because the information obtained by this service contributed to higher vaccination rates. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.